Psychotropic medications familiar to psychiatrists as having potential teratogenic risks (diazepam, lithium, carbamazepine, valproic acid) are discussed cogently, with risks ranging from unlikely (fluoxetine) to minimal (diazepam) to moderate (carbamazepine, valproic acid) to high (alcohol) and fair to good ratings of the quality and quantity of data supporting these conclusions. However, possibly disconcerting to the clinician are the numerous psychiatric drugs listed (e.g., clozapine, nefazodone, bupropion, venlafaxine) as having an undetermined risk for congenital defects with very limited or no data. (Olanzapine and quetiapine are not among the medications discussed, probably because the book has a 1998 publication date.) Equally troubling is that the information provided on the effects of medications on breast-fed infants varies widely. Many drugs have some information on the amount of drug ingested by nursing infants (generally based on case reports) but little else. Data on long-term consequences of such ingestion is extremely limited. The authors note that most psychiatric medications are regarded by the American Academy of Pediatrics as a concern "because of potential to alter CNS functioning." As the authors point out, there is little evidence supporting (or refuting) this concern.